01.05.26 -- CGT Industrialization Starts With CDMO Alignment

Ensure your cell therapy program is prepared for the future by learning how to effectively navigate sourcing, logistics, and manufacturing challenges with confidence.

Selecting the right CDMO is critical for biopharma success. The ideal partner offers end-to-end capabilities, scientific expertise, quality culture, agility, and transparent collaboration from concept to commercialization.

When manufacturing adeno-associated virus, lenti- and adenoviral vectors, see how this HEK293 cell line is optimized for suspension culture and viral vector production, which can significantly reduce costs.

Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.

Explore considerations for phase-appropriate AAV characterization and release activities from pre-clinical to late-phase products. Review validation challenges and paths for maturation of analytics.

Discover how expert formulation and analytical support enable the development of stable, injectable oligonucleotide therapies across diverse delivery routes and molecule types.

Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.

Leverage advanced elemental impurity testing methods to ensure the safety, compliance, and accuracy of your drug products throughout the manufacturing process.